SPRL--A MOLECULAR MARKER FOR BRONCHIAL PRENEOPLASIA
SPRL--支气管癌前病变的分子标记
基本信息
- 批准号:2733198
- 负责人:
- 金额:$ 8.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1996
- 资助国家:美国
- 起止时间:1996-07-01 至 2000-06-30
- 项目状态:已结题
- 来源:
- 关键词:DNA footprinting biomarker bronchus neoplasm cell transformation cellular oncology gel mobility shift assay gene expression genetic regulatory element human tissue immunocytochemistry in situ hybridization metastasis molecular cloning nuclear runoff assay oncoproteins preneoplastic state proline respiratory epithelium squamous cell carcinoma tissue /cell culture transcription factor
项目摘要
DESCRIPTION (Applicant's Description): This program is designed to
establish the applicant as an independent investigator of biomarker research
in bronchial carcinogenesis, and in early detection and chemoprevention of
cancers of the upper aerodigestive tract. The applicant has previous
research experience in molecular and cellular pharmacology and has recently
become an established medical oncologist specializing in the treatment of
lung cancer. The sponsor is an accomplished pulmonary physiologist and
molecular biologist in the field of development and differentiation of
bronchial epithelium, and in the area of regulation of biomarkers of the
bronchial epithelium in response to environmental toxins such as ozone and
tobacco smoke. The plans of the sponsor are to provide supervision to the
applicant to acquire expertise in molecular techniques, in the design and
execution of experiments to elucidate the mechanisms of regulation of a
molecular marker, spr1, associated with bronchial metaplasia, and in the
application of this biomarker for early detection of lung cancer.
The sponsor has cloned a small proline-rich protein (spr-1) which is
overexpressed in tracheobronchial epithelium undergoing metaplastic change
from a normal mucociliary phenotype to a squamous appearance. The spr1
expression is down-regulated by vitamin A and up-regulated by tumor
promoters. Therefore, it appears that spr1 is a potential early biomarker
for preneoplastic transformation of the bronchial epithelium. In their
laboratory, there is a series of human bronchial epithelial cells displaying
varied degree of spr1 expression and tumorigenicity potential. This
proposal is, thus, intended to use this cell-culture model to elucidate the
mechanism of regulation of spr1 expression in the multistep carcinogenesis
of the bronchial epithelium, and to use archival specimens to map spr1
expression in the field of cancerization of lung tissues from patients with
lung cancer.
The first aim is to test the hypothesis that there is an increasing
expression of spr1 in the field of cancerization extending from a focus of
bronchial squamous carcinoma to the surrounding dysplastic, metaplastic and
normal bronchial epithelia as determined by immunohistochemical staining and
in situ hybridization of archival human squamous lung carcinoma. The second
aim is to use a human tracheobronchial cell model to test the hypothesis
that the cell type-specific expression of spr1 is regulated at the level of
transcription by using a nuclear run-on transcriptional assay and a
transfection study with chimeric constructs of the spr1 promoter region
attached to a reporter gene. The third aim is to identify the cis-elements
and the transcriptional factors involved in the regulation of spr1 gene by
employing the techniques of DNA-binding mobility shift gel assay, DNA
footprinting and expression cloning.
These studies are to set the stage for using spr1 as a biomarker for
identifying the early steps of multistep carcinogenesis, for early detection
of lung cancer, and for testing the efficacy and mechanisms of
chemopreventive agents in reversing malignant transformation of the
bronchial epithelium.
描述(申请者描述):该计划旨在
确立申请人为生物标记物研究的独立调查者
在肺癌的发生、早期发现和化学预防中的作用
上呼吸道癌症。申请人以前有过
在分子和细胞药理学方面的研究经验,最近
成为一名成熟的内科肿瘤学家,专门治疗
肺癌。赞助商是一位有成就的肺部生理学家,
发育和分化领域的分子生物学家
支气管上皮,以及在调节生物标志物的领域
支气管上皮对环境毒素如臭氧和
烟草烟雾。发起人的计划是监督
申请人在分子技术、设计和技术方面获得专门知识
进行实验以阐明调节A蛋白的机制
与支气管化生相关的分子标志物SPR1,以及在
该生物标志物在肺癌早期检测中的应用。
赞助商已经克隆了一个富含脯氨酸的小蛋白(spr-1),它是
化生过程中气管、支气管壁上皮的过度表达
从正常的粘液纤毛表型到鳞状外观。SPR1
维生素A下调表达,肿瘤上调表达
推动者。因此,SPR1可能是一个潜在的早期生物标志物。
用于支气管上皮的癌前转化。在他们的
实验室里,有一系列的人支气管上皮细胞展示
不同程度的SPR1表达和致瘤性。这
因此,该提案旨在利用这种细胞培养模型来阐明
SPR1在多步致癌中的表达调控机制
并使用档案标本来绘制SPR1图
肺癌患者肺组织癌变过程中的表达
肺癌。
第一个目标是检验这一假设,即
SPR1在癌变过程中的表达
支气管鳞癌向周围不典型增生、化生和
免疫组织化学染色和免疫组织化学方法检测正常支气管上皮
人肺鳞状细胞癌的原位杂交研究。第二
目的是使用人类气管、支气管细胞模型来检验这一假说
SPR1的细胞类型特异性表达在
通过使用核连续转录分析和一个
SPR1启动子区域嵌合构建的转基因研究
依附于一种记者基因。第三个目标是确定顺式要素
以及参与SPR1基因调控的转录因子
利用DNA结合迁移率变化凝胶分析技术,
足迹和表达克隆。
这些研究是为将SPR1用作生物标志物奠定基础
识别多步致癌的早期步骤,以便早期发现
治疗肺癌,并测试其疗效和机制。
化学预防药物逆转卵巢癌恶变的研究
支气管上皮细胞。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DERICK LAU其他文献
DERICK LAU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DERICK LAU', 18)}}的其他基金
DOSAGE COMPARISON STUDY OF BMS-274183 IN PATIENTS WITH PRE-TREATED, NON-SMALL
BMS-274183 在已接受治疗的非小患者中的剂量比较研究
- 批准号:
7203181 - 财政年份:2005
- 资助金额:
$ 8.65万 - 项目类别:
Capturing cancer cells with peptide bead technology
利用肽珠技术捕获癌细胞
- 批准号:
6446600 - 财政年份:2002
- 资助金额:
$ 8.65万 - 项目类别:
Capturing cancer cells with peptide bead technology
利用肽珠技术捕获癌细胞
- 批准号:
6622462 - 财政年份:2002
- 资助金额:
$ 8.65万 - 项目类别:
SPRL--A MOLECULAR MARKER FOR BRONCHIAL PRENEOPLASIA
SPRL--支气管癌前病变的分子标记
- 批准号:
2443219 - 财政年份:1996
- 资助金额:
$ 8.65万 - 项目类别:
SPRL--A MOLECULAR MARKER FOR BRONCHIAL PRENEOPLASIA
SPRL--支气管癌前病变的分子标记
- 批准号:
2895441 - 财政年份:1996
- 资助金额:
$ 8.65万 - 项目类别:
相似国自然基金
基于DNA甲基化交互网络的癌症hallmark挖掘及其在癌症转移biomarker筛选中的应用
- 批准号:61602201
- 批准年份:2016
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
血清miRNAs成为一种新的biomarker在PD诊断中的价值和LRRK2基因调控的机制研究
- 批准号:81170309
- 批准年份:2011
- 资助金额:50.0 万元
- 项目类别:面上项目
非小细胞肺癌Biomarker的Imaging MS研究新方法
- 批准号:30672394
- 批准年份:2006
- 资助金额:30.0 万元
- 项目类别:面上项目
相似海外基金
酸化ストレス応答アポトーシス誘導蛋白のUCに対する新規Biomarker探索と治療への展開
寻找治疗 UC 的氧化应激反应性凋亡诱导蛋白的新生物标志物并开发治疗方法
- 批准号:
24K11919 - 财政年份:2024
- 资助金额:
$ 8.65万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
肝内胆管癌新規Biomarkerの同定及び癌周囲間質を標的とした新規治療開発
鉴定肝内胆管癌的新型生物标志物并开发针对癌周基质的新疗法
- 批准号:
24K19350 - 财政年份:2024
- 资助金额:
$ 8.65万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
収縮能が保たれた心不全の機械学習分類とmicroRNAなどのbiomarkerの探索
机器学习对具有保留收缩性的心力衰竭进行分类并搜索 microRNA 等生物标志物
- 批准号:
24K19007 - 财政年份:2024
- 资助金额:
$ 8.65万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of a predictive biomarker for Parkinson's disease
帕金森病预测生物标志物的开发
- 批准号:
MR/Y019415/1 - 财政年份:2024
- 资助金额:
$ 8.65万 - 项目类别:
Research Grant
Sleep and circadian dysfunction in ageing and neurodegeneration: a life course and biomarker study of the British 1946 birth cohort.
衰老和神经退行性疾病中的睡眠和昼夜节律功能障碍:对英国 1946 年出生队列的生命历程和生物标志物研究。
- 批准号:
MR/Y009452/1 - 财政年份:2024
- 资助金额:
$ 8.65万 - 项目类别:
Fellowship
Biomarker-Based Platform for Early Diagnosis of Chronic Liver Disease to Enable Personalized Therapy (LIVERAIM)
基于生物标志物的慢性肝病早期诊断平台,以实现个性化治疗(LIVERAIM)
- 批准号:
10087822 - 财政年份:2024
- 资助金额:
$ 8.65万 - 项目类别:
EU-Funded
Enhanced stratification of COPD patients via integration of a digitally enabled biomarker Point-of-Care test within a Remote Patient Monitoring tool
通过在远程患者监测工具中集成数字化生物标志物即时检测,增强 COPD 患者的分层
- 批准号:
10098600 - 财政年份:2024
- 资助金额:
$ 8.65万 - 项目类别:
Collaborative R&D
QuBIE: Quantitative Biomarker Identification for Non-Endoscopic Prediction and Monitoring of Treatment Response in Eosinophilic Oesophagitis
QuBIE:用于非内镜预测和监测嗜酸性食管炎治疗反应的定量生物标志物鉴定
- 批准号:
10083253 - 财政年份:2024
- 资助金额:
$ 8.65万 - 项目类别:
Collaborative R&D
膵癌腫瘍内線維化に着目した術前化学療法効果予測に関する画像biomarkerの確立
建立预测胰腺癌瘤内纤维化术前化疗效果的影像生物标志物
- 批准号:
24K18824 - 财政年份:2024
- 资助金额:
$ 8.65万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Multi-modal non-invasive biomarker screening for high-risk undiagnosed liver disease
针对高危未确诊肝病的多模式非侵入性生物标志物筛查
- 批准号:
10073169 - 财政年份:2023
- 资助金额:
$ 8.65万 - 项目类别:
Collaborative R&D














{{item.name}}会员




